Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, produced by Streptomyces strains | 276 | 83905-01-5 |
Dose | Unit | Route |
---|---|---|
0.30 | g | O |
0.50 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 39 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 6 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 44.50 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 34 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 33 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.88 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 69 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 1, 1991 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 4480.92 | 26.05 | 1139 | 2472 | 45504 | 2308970 |
No adverse event | 424.64 | 26.05 | 132 | 3479 | 9396 | 2345078 |
Rash | 396.45 | 26.05 | 209 | 3402 | 59349 | 2295125 |
Product quality issue | 308.32 | 26.05 | 107 | 3504 | 10722 | 2343752 |
Product packaging quantity issue | 283.76 | 26.05 | 52 | 3559 | 338 | 2354136 |
Product dose omission | 244.18 | 26.05 | 131 | 3480 | 38126 | 2316348 |
Vomiting | 230.77 | 26.05 | 158 | 3453 | 71444 | 2283030 |
Urticaria | 221.71 | 26.05 | 106 | 3505 | 24155 | 2330319 |
Nausea | 199.86 | 26.05 | 174 | 3437 | 112015 | 2242459 |
Drug-induced liver injury | 197.41 | 26.05 | 59 | 3552 | 3640 | 2350834 |
Diarrhoea | 188.98 | 26.05 | 149 | 3462 | 83415 | 2271059 |
Anosmia | 181.05 | 26.05 | 41 | 3570 | 831 | 2353643 |
Stevens-Johnson syndrome | 168.43 | 26.05 | 54 | 3557 | 4205 | 2350269 |
Inappropriate schedule of product administration | 161.03 | 26.05 | 69 | 3542 | 12135 | 2342339 |
Drug interaction | 147.80 | 26.05 | 86 | 3525 | 29077 | 2325397 |
Pyrexia | 145.78 | 26.05 | 107 | 3504 | 53601 | 2300873 |
Ageusia | 142.72 | 26.05 | 40 | 3571 | 1958 | 2352516 |
Pruritus | 142.23 | 26.05 | 97 | 3514 | 43243 | 2311231 |
Electrocardiogram QT prolonged | 136.40 | 26.05 | 54 | 3557 | 7760 | 2346714 |
Drug ineffective | 132.84 | 26.05 | 133 | 3478 | 101491 | 2252983 |
Dyspnoea | 131.33 | 26.05 | 118 | 3493 | 78615 | 2275859 |
Hypersensitivity | 112.65 | 26.05 | 67 | 3544 | 23526 | 2330948 |
Torsade de pointes | 111.89 | 26.05 | 34 | 3577 | 2212 | 2352262 |
Deafness | 109.83 | 26.05 | 35 | 3576 | 2666 | 2351808 |
Cardiac arrest | 105.78 | 26.05 | 55 | 3556 | 14875 | 2339599 |
Tinnitus | 98.43 | 26.05 | 38 | 3573 | 5097 | 2349377 |
Eye irritation | 96.96 | 26.05 | 34 | 3577 | 3478 | 2350996 |
Erythema | 88.76 | 26.05 | 59 | 3552 | 25100 | 2329374 |
Malaise | 87.88 | 26.05 | 81 | 3530 | 55504 | 2298970 |
Abdominal pain | 85.22 | 26.05 | 65 | 3546 | 34309 | 2320165 |
Ventricular fibrillation | 83.24 | 26.05 | 27 | 3584 | 2174 | 2352300 |
Acute kidney injury | 80.50 | 26.05 | 58 | 3553 | 28064 | 2326410 |
Incorrect product administration duration | 75.99 | 26.05 | 26 | 3585 | 2469 | 2352005 |
Ocular hyperaemia | 74.11 | 26.05 | 29 | 3582 | 4027 | 2350447 |
International normalised ratio increased | 69.63 | 26.05 | 33 | 3578 | 7303 | 2347171 |
Drug reaction with eosinophilia and systemic symptoms | 68.73 | 26.05 | 30 | 3581 | 5488 | 2348986 |
Product prescribing error | 67.93 | 26.05 | 25 | 3586 | 2935 | 2351539 |
Chills | 65.99 | 26.05 | 41 | 3570 | 15511 | 2338963 |
Pneumonia | 64.89 | 26.05 | 65 | 3546 | 49231 | 2305243 |
Ventricular tachycardia | 63.86 | 26.05 | 24 | 3587 | 2987 | 2351487 |
Toxic epidermal necrolysis | 62.85 | 26.05 | 24 | 3587 | 3120 | 2351354 |
Alanine aminotransferase increased | 62.09 | 26.05 | 38 | 3573 | 13994 | 2340480 |
Abdominal discomfort | 61.65 | 26.05 | 41 | 3570 | 17415 | 2337059 |
Dizziness | 60.62 | 26.05 | 68 | 3543 | 58597 | 2295877 |
Hepatocellular injury | 60.29 | 26.05 | 25 | 3586 | 4030 | 2350444 |
Anaphylactic shock | 58.95 | 26.05 | 25 | 3586 | 4261 | 2350213 |
Aspartate aminotransferase increased | 57.97 | 26.05 | 35 | 3576 | 12577 | 2341897 |
Seizure | 57.79 | 26.05 | 45 | 3566 | 24421 | 2330053 |
Palpitations | 56.54 | 26.05 | 38 | 3573 | 16418 | 2338056 |
Cough | 55.61 | 26.05 | 50 | 3561 | 33067 | 2321407 |
Condition aggravated | 53.13 | 26.05 | 48 | 3563 | 31931 | 2322543 |
Syncope | 50.97 | 26.05 | 36 | 3575 | 16839 | 2337635 |
Eye pain | 49.48 | 26.05 | 23 | 3588 | 4868 | 2349606 |
Tachycardia | 47.24 | 26.05 | 34 | 3577 | 16375 | 2338099 |
Hypoacusis | 47.17 | 26.05 | 20 | 3591 | 3405 | 2351069 |
Eye swelling | 45.51 | 26.05 | 21 | 3590 | 4369 | 2350105 |
Erythema multiforme | 44.89 | 26.05 | 17 | 3594 | 2158 | 2352316 |
Hypotension | 44.89 | 26.05 | 44 | 3567 | 32392 | 2322082 |
Medication error | 44.54 | 26.05 | 23 | 3588 | 6108 | 2348366 |
Abdominal pain upper | 44.42 | 26.05 | 37 | 3574 | 22063 | 2332411 |
Bradycardia | 44.05 | 26.05 | 27 | 3584 | 9954 | 2344520 |
Pharyngeal oedema | 43.51 | 26.05 | 19 | 3592 | 3474 | 2351000 |
Loss of consciousness | 43.17 | 26.05 | 34 | 3577 | 18733 | 2335741 |
Pancytopenia | 43.09 | 26.05 | 28 | 3583 | 11424 | 2343050 |
Anaphylactic reaction | 42.19 | 26.05 | 26 | 3585 | 9679 | 2344795 |
Weight decreased | 42.10 | 26.05 | 40 | 3571 | 28331 | 2326143 |
Throat tightness | 39.17 | 26.05 | 19 | 3592 | 4417 | 2350057 |
Toxicity to various agents | 39.05 | 26.05 | 41 | 3570 | 32713 | 2321761 |
Hepatitis cholestatic | 38.93 | 26.05 | 13 | 3598 | 1144 | 2353330 |
Lip oedema | 38.62 | 26.05 | 12 | 3599 | 839 | 2353635 |
Angioedema | 37.78 | 26.05 | 23 | 3588 | 8373 | 2346101 |
Blood alkaline phosphatase increased | 37.58 | 26.05 | 21 | 3590 | 6524 | 2347950 |
Palmar erythema | 37.46 | 26.05 | 9 | 3602 | 237 | 2354237 |
Liver injury | 36.88 | 26.05 | 15 | 3596 | 2299 | 2352175 |
Monoclonal gammopathy | 36.84 | 26.05 | 8 | 3603 | 132 | 2354342 |
Aphthous ulcer | 36.34 | 26.05 | 13 | 3598 | 1405 | 2353069 |
Tremor | 36.24 | 26.05 | 32 | 3579 | 20629 | 2333845 |
Cholestasis | 36.09 | 26.05 | 17 | 3594 | 3704 | 2350770 |
Pallor | 36.00 | 26.05 | 17 | 3594 | 3725 | 2350749 |
Cardio-respiratory arrest | 35.97 | 26.05 | 23 | 3588 | 9123 | 2345351 |
Hypoxic-ischaemic encephalopathy | 35.51 | 26.05 | 11 | 3600 | 761 | 2353713 |
Deafness neurosensory | 34.85 | 26.05 | 10 | 3601 | 531 | 2353943 |
Hepatic failure | 34.71 | 26.05 | 19 | 3592 | 5670 | 2348804 |
Adjustment disorder | 34.54 | 26.05 | 8 | 3603 | 179 | 2354295 |
Rhabdomyolysis | 34.43 | 26.05 | 20 | 3591 | 6684 | 2347790 |
Paraesthesia | 34.40 | 26.05 | 32 | 3579 | 22056 | 2332418 |
Respiratory failure | 34.35 | 26.05 | 26 | 3585 | 13502 | 2340972 |
Burning sensation | 34.09 | 26.05 | 21 | 3590 | 7807 | 2346667 |
Agranulocytosis | 34.05 | 26.05 | 16 | 3595 | 3466 | 2351008 |
Rash maculo-papular | 33.93 | 26.05 | 17 | 3594 | 4235 | 2350239 |
Actinic keratosis | 33.48 | 26.05 | 9 | 3602 | 375 | 2354099 |
Asthenia | 33.18 | 26.05 | 45 | 3566 | 46881 | 2307593 |
Vision blurred | 32.49 | 26.05 | 26 | 3585 | 14642 | 2339832 |
Cyanosis | 32.27 | 26.05 | 15 | 3596 | 3170 | 2351304 |
Swelling | 32.06 | 26.05 | 27 | 3584 | 16323 | 2338151 |
Insomnia | 32.01 | 26.05 | 33 | 3578 | 25754 | 2328720 |
Drug eruption | 31.94 | 26.05 | 15 | 3596 | 3244 | 2351230 |
Bronchitis | 31.86 | 26.05 | 25 | 3586 | 13689 | 2340785 |
Ototoxicity | 31.62 | 26.05 | 8 | 3603 | 262 | 2354212 |
Hyperhidrosis | 31.34 | 26.05 | 26 | 3585 | 15396 | 2339078 |
Sacroiliitis | 31.22 | 26.05 | 8 | 3603 | 276 | 2354198 |
White blood cell count increased | 30.85 | 26.05 | 19 | 3592 | 7059 | 2347415 |
Acute generalised exanthematous pustulosis | 30.78 | 26.05 | 12 | 3599 | 1646 | 2352828 |
Headache | 30.59 | 26.05 | 58 | 3553 | 80121 | 2274353 |
Dermatitis exfoliative | 30.39 | 26.05 | 11 | 3600 | 1230 | 2353244 |
Hepatitis | 30.16 | 26.05 | 18 | 3593 | 6319 | 2348155 |
Wheezing | 30.04 | 26.05 | 18 | 3593 | 6366 | 2348108 |
Atrophy | 29.79 | 26.05 | 8 | 3603 | 332 | 2354142 |
Sinusitis | 29.78 | 26.05 | 26 | 3585 | 16500 | 2337974 |
Conjunctivitis | 29.75 | 26.05 | 13 | 3598 | 2380 | 2352094 |
Back pain | 29.74 | 26.05 | 35 | 3576 | 31624 | 2322850 |
Drug intolerance | 29.71 | 26.05 | 24 | 3587 | 13693 | 2340781 |
Hemianopia heteronymous | 29.28 | 26.05 | 5 | 3606 | 20 | 2354454 |
Foetal death | 29.13 | 26.05 | 12 | 3599 | 1900 | 2352574 |
Bundle branch block left | 28.96 | 26.05 | 10 | 3601 | 974 | 2353500 |
Hepatitis acute | 28.11 | 26.05 | 11 | 3600 | 1524 | 2352950 |
Chromaturia | 28.00 | 26.05 | 13 | 3598 | 2740 | 2351734 |
Pyloric stenosis | 27.52 | 26.05 | 6 | 3605 | 101 | 2354373 |
Coagulopathy | 27.32 | 26.05 | 13 | 3598 | 2896 | 2351578 |
Ear discomfort | 27.19 | 26.05 | 10 | 3601 | 1170 | 2353304 |
Eosinophilia | 27.06 | 26.05 | 13 | 3598 | 2957 | 2351517 |
Hallucination, visual | 27.02 | 26.05 | 13 | 3598 | 2966 | 2351508 |
Laryngeal oedema | 26.33 | 26.05 | 10 | 3601 | 1278 | 2353196 |
Tubulointerstitial nephritis | 26.32 | 26.05 | 12 | 3599 | 2426 | 2352048 |
Hepatic steatosis | 26.09 | 26.05 | 13 | 3598 | 3200 | 2351274 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 705.16 | 29.83 | 217 | 2038 | 14918 | 1729608 |
No adverse event | 329.14 | 29.83 | 95 | 2160 | 5087 | 1739439 |
Drug interaction | 249.67 | 29.83 | 121 | 2134 | 27837 | 1716689 |
Rash | 215.29 | 29.83 | 122 | 2133 | 38571 | 1705955 |
Product quality issue | 205.92 | 29.83 | 69 | 2186 | 6024 | 1738502 |
Product packaging quantity issue | 193.13 | 29.83 | 36 | 2219 | 251 | 1744275 |
Vomiting | 150.98 | 29.83 | 97 | 2158 | 38218 | 1706308 |
Product dose omission | 138.50 | 29.83 | 76 | 2179 | 22364 | 1722162 |
Stevens-Johnson syndrome | 137.39 | 29.83 | 44 | 2211 | 3313 | 1741213 |
Diarrhoea | 134.31 | 29.83 | 103 | 2152 | 53749 | 1690777 |
Rhabdomyolysis | 119.88 | 29.83 | 55 | 2200 | 11035 | 1733491 |
Pruritus | 119.87 | 29.83 | 70 | 2185 | 23152 | 1721374 |
Electrocardiogram QT prolonged | 115.78 | 29.83 | 44 | 2211 | 5501 | 1739025 |
International normalised ratio increased | 114.95 | 29.83 | 49 | 2206 | 8250 | 1736276 |
Dyspnoea | 113.34 | 29.83 | 92 | 2163 | 51967 | 1692559 |
Urticaria | 111.66 | 29.83 | 54 | 2201 | 12187 | 1732339 |
Pyrexia | 107.31 | 29.83 | 85 | 2170 | 46315 | 1698211 |
Inappropriate schedule of product administration | 106.47 | 29.83 | 45 | 2210 | 7414 | 1737112 |
Vanishing bile duct syndrome | 94.65 | 29.83 | 18 | 2237 | 141 | 1744385 |
Drug-induced liver injury | 90.98 | 29.83 | 32 | 2223 | 3205 | 1741321 |
Abdominal pain | 90.72 | 29.83 | 57 | 2198 | 21433 | 1723093 |
Deafness | 89.62 | 29.83 | 28 | 2227 | 1938 | 1742588 |
Pneumonia | 88.67 | 29.83 | 76 | 2179 | 46106 | 1698420 |
Nausea | 85.82 | 29.83 | 78 | 2177 | 51118 | 1693408 |
Cholestasis | 79.76 | 29.83 | 30 | 2225 | 3635 | 1740891 |
Drug eruption | 78.69 | 29.83 | 28 | 2227 | 2898 | 1741628 |
Jaundice | 77.98 | 29.83 | 34 | 2221 | 6028 | 1738498 |
Condition aggravated | 74.25 | 29.83 | 50 | 2205 | 21100 | 1723426 |
Hypersensitivity | 71.52 | 29.83 | 38 | 2217 | 10406 | 1734120 |
Cough | 71.27 | 29.83 | 47 | 2208 | 19150 | 1725376 |
Hepatomegaly | 68.51 | 29.83 | 22 | 2233 | 1663 | 1742863 |
Skin exfoliation | 66.77 | 29.83 | 28 | 2227 | 4507 | 1740019 |
Aspartate aminotransferase increased | 64.92 | 29.83 | 36 | 2219 | 10720 | 1733806 |
Alanine aminotransferase increased | 63.11 | 29.83 | 37 | 2218 | 12241 | 1732285 |
Viral infection | 56.95 | 29.83 | 22 | 2233 | 2861 | 1741665 |
Clostridium difficile colitis | 53.36 | 29.83 | 18 | 2237 | 1586 | 1742940 |
Prothrombin level decreased | 52.54 | 29.83 | 12 | 2243 | 244 | 1744282 |
Angioedema | 51.96 | 29.83 | 30 | 2225 | 9634 | 1734892 |
Tinnitus | 51.32 | 29.83 | 21 | 2234 | 3174 | 1741352 |
Drug ineffective | 51.29 | 29.83 | 66 | 2189 | 63735 | 1680791 |
Tubulointerstitial nephritis | 49.42 | 29.83 | 20 | 2235 | 2938 | 1741588 |
Torsade de pointes | 48.59 | 29.83 | 16 | 2239 | 1308 | 1743218 |
Drug reaction with eosinophilia and systemic symptoms | 48.03 | 29.83 | 23 | 2232 | 5047 | 1739479 |
Incorrect product administration duration | 47.94 | 29.83 | 15 | 2240 | 1040 | 1743486 |
Ventricular tachycardia | 47.82 | 29.83 | 21 | 2234 | 3777 | 1740749 |
Cardiac arrest | 47.25 | 29.83 | 34 | 2221 | 15896 | 1728630 |
Loss of consciousness | 47.00 | 29.83 | 33 | 2222 | 14842 | 1729684 |
Bacterial infection | 46.61 | 29.83 | 17 | 2238 | 1885 | 1742641 |
Acute kidney injury | 46.49 | 29.83 | 47 | 2208 | 34897 | 1709629 |
Hepatitis | 45.48 | 29.83 | 22 | 2233 | 4933 | 1739593 |
Anosmia | 45.24 | 29.83 | 12 | 2243 | 460 | 1744066 |
Palpitations | 44.37 | 29.83 | 24 | 2231 | 6790 | 1737736 |
Off label use | 44.37 | 29.83 | 48 | 2207 | 38523 | 1706003 |
Mycobacterium avium complex infection | 44.16 | 29.83 | 11 | 2244 | 327 | 1744199 |
Weight decreased | 42.54 | 29.83 | 37 | 2218 | 22716 | 1721810 |
Leukopenia | 42.08 | 29.83 | 25 | 2230 | 8455 | 1736071 |
Blood creatine phosphokinase increased | 41.07 | 29.83 | 25 | 2230 | 8831 | 1735695 |
Eye irritation | 39.88 | 29.83 | 14 | 2241 | 1389 | 1743137 |
Haemolytic anaemia | 39.60 | 29.83 | 15 | 2240 | 1847 | 1742679 |
Toxic epidermal necrolysis | 39.49 | 29.83 | 16 | 2239 | 2355 | 1742171 |
Pseudomembranous colitis | 39.44 | 29.83 | 11 | 2244 | 510 | 1744016 |
Product prescribing error | 39.24 | 29.83 | 16 | 2239 | 2394 | 1742132 |
Erythema | 39.15 | 29.83 | 29 | 2226 | 14159 | 1730367 |
Rash maculo-papular | 38.75 | 29.83 | 18 | 2237 | 3685 | 1740841 |
Blood alkaline phosphatase increased | 38.64 | 29.83 | 20 | 2235 | 5175 | 1739351 |
Hepatocellular injury | 37.89 | 29.83 | 17 | 2238 | 3214 | 1741312 |
Chromaturia | 37.77 | 29.83 | 16 | 2239 | 2634 | 1741892 |
Multiple organ dysfunction syndrome | 37.58 | 29.83 | 24 | 2231 | 9218 | 1735308 |
Swollen tongue | 36.88 | 29.83 | 16 | 2239 | 2792 | 1741734 |
Hepatitis cholestatic | 36.85 | 29.83 | 13 | 2242 | 1308 | 1743218 |
Hepatic failure | 36.23 | 29.83 | 20 | 2235 | 5883 | 1738643 |
Hypotension | 35.99 | 29.83 | 38 | 2217 | 29616 | 1714910 |
Hepatic function abnormal | 35.46 | 29.83 | 21 | 2234 | 7053 | 1737473 |
Blood bilirubin increased | 35.29 | 29.83 | 20 | 2235 | 6190 | 1738336 |
Bronchitis | 34.99 | 29.83 | 19 | 2236 | 5413 | 1739113 |
Transaminases increased | 34.76 | 29.83 | 17 | 2238 | 3900 | 1740626 |
Ageusia | 34.63 | 29.83 | 13 | 2242 | 1561 | 1742965 |
Respiratory failure | 34.19 | 29.83 | 27 | 2228 | 14478 | 1730048 |
Hepatic enzyme increased | 34.09 | 29.83 | 20 | 2235 | 6601 | 1737925 |
Erythema multiforme | 33.32 | 29.83 | 13 | 2242 | 1733 | 1742793 |
Agranulocytosis | 33.18 | 29.83 | 16 | 2239 | 3560 | 1740966 |
Tachycardia | 33.02 | 29.83 | 25 | 2230 | 12603 | 1731923 |
Activated partial thromboplastin time prolonged | 33.00 | 29.83 | 12 | 2243 | 1318 | 1743208 |
Renal failure | 32.35 | 29.83 | 30 | 2225 | 19987 | 1724539 |
Uveitis | 31.84 | 29.83 | 11 | 2244 | 1040 | 1743486 |
Decreased appetite | 31.49 | 29.83 | 32 | 2223 | 23839 | 1720687 |
Hyperhidrosis | 31.06 | 29.83 | 24 | 2231 | 12464 | 1732062 |
Visual field defect | 30.82 | 29.83 | 11 | 2244 | 1145 | 1743381 |
Ventricular fibrillation | 30.72 | 29.83 | 14 | 2241 | 2742 | 1741784 |
Dermatitis bullous | 30.20 | 29.83 | 11 | 2244 | 1213 | 1743313 |
Source | Code | Description |
---|---|---|
ATC | J01FA10 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Macrolides |
ATC | J01RA07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
ATC | S01AA26 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics |
FDA EPC | N0000175935 | Macrolide Antimicrobial |
FDA Chemical/Ingredient | N0000007529 | Macrolides |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
Acute gonococcal urethritis | indication | 29864006 | |
Streptococcal tonsillitis | indication | 41582007 | |
Pneumonia due to Mycoplasma pneumoniae | indication | 46970008 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Acute bacterial sinusitis | indication | 75498004 | |
Bacterial conjunctivitis | indication | 128350005 | DOID:9700 |
Urethritis due to Chlamydia trachomatis | indication | 179101003 | |
Pulmonary Mycobacterium avium complex infection | indication | 186342000 | |
Chlamydial pelvic inflammatory disease | indication | 188463006 | |
Acute bacterial bronchitis | indication | 233598009 | |
Pneumococcal pneumonia | indication | 233607000 | |
Chlamydial pneumonia | indication | 233609002 | |
Chancroid | indication | 266143009 | DOID:13778 |
Pelvic inflammatory disease due to Mycoplasma hominis | indication | 270550006 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Infective otitis media | indication | 312218008 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Acute exacerbation of chronic bronchitis | indication | 425748003 | |
Pneumonia due to Staphylococcus aureus | indication | 441658007 | |
Moraxella Catarrhalis Acute Otitis Media | indication | ||
Skin and Skin Structure Streptococcus Agalactiae Infection | indication | ||
Chlamydia Cervicitis | indication | ||
Legionella Pneumophila Pneumonia | indication | ||
Pelvic Inflammatory Disease with Neisseria Gonorrhea | indication | ||
Pneumococcal Acute Otitis Media | indication | ||
Haemophilus Influenzae Acute Otitis Media | indication | ||
Moraxella Catarrhalis Pneumonia | indication | ||
Pyrexia of unknown origin | off-label use | 7520000 | |
Traveler's diarrhea | off-label use | 11840006 | |
Enteric campylobacteriosis | off-label use | 18081009 | |
Pertussis | off-label use | 27836007 | |
Gonorrhea of rectum | off-label use | 42746002 | |
Gonorrhea of pharynx | off-label use | 74372003 | |
Coronavirus infection | off-label use | 186747009 | |
Boutonneuse fever | off-label use | 186774005 | DOID:14095 |
Toxoplasmosis associated with acquired immunodeficiency syndrome | off-label use | 421666009 | |
Prevention of Bacterial Endocarditis | off-label use | ||
Inflammatory Disease of Female Pelvic Organs | off-label use | ||
Sexual Transmitted Disease Exposure from Sexual Assault | off-label use | ||
Jaundice | contraindication | 18165001 | |
Torsades de pointes | contraindication | 31722008 | |
Chronic heart failure | contraindication | 48447003 | |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Prolonged QT interval | contraindication | 111975006 | |
Hearing disorder | contraindication | 128540005 | |
Liver function tests abnormal | contraindication | 166603001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Congenital long QT syndrome | contraindication | 442917000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.45 | acidic |
pKa2 | 8.87 | Basic |
pKa3 | 8.24 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 2GM BASE/BOT | ZMAX | PF PRISM CV | N050797 | June 10, 2005 | DISCN | FOR SUSPENSION, EXTENDED RELEASE | ORAL | 6984403 | Feb. 14, 2024 | METHOD OF TREATING BACTERIAL INFECTIONS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Canalicular multispecific organic anion transporter 1 | Transporter | IC50 | 4.16 | WOMBAT-PK | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 3.70 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 3.39 | WOMBAT-PK | |||||
Motilin receptor | GPCR | AGONIST | EC50 | 5.50 | IUPHAR | ||||
SARS-CoV-2 | Virus | INHIBITOR | EC50 | 5.67 | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
4020019 | VUID |
N0000148074 | NUI |
C0052796 | UMLSCUI |
D02134 | KEGG_DRUG |
5FD1131I7S | UNII |
117772-70-0 | SECONDARY_CAS_RN |
96034006 | SNOMEDCT_US |
4020019 | VANDF |
72442 | MMSL |
003635 | NDDF |
18631 | RXNORM |
387531004 | SNOMEDCT_US |
4238 | MMSL |
d00091 | MMSL |
CHEMBL529 | ChEMBL_ID |
DB00207 | DRUGBANK_ID |
CHEMBL1200502 | ChEMBL_ID |
6197 | INN_ID |
ZIT | PDB_CHEM_ID |
6510 | IUPHAR_LIGAND_ID |
D017963 | MESH_DESCRIPTOR_UI |
447043 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0400 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | NDA | 17 sections |
ZITHROMAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3051 | POWDER, FOR SUSPENSION | 1 g | ORAL | NDA | 18 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3060 | TABLET, FILM COATED | 250 mg | ORAL | NDA | 17 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3070 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 17 sections |
ZITHROMAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3080 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 18 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3110 | POWDER, FOR SUSPENSION | 100 mg | ORAL | NDA | 17 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3120 | POWDER, FOR SUSPENSION | 200 mg | ORAL | NDA | 17 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3130 | POWDER, FOR SUSPENSION | 200 mg | ORAL | NDA | 17 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3140 | POWDER, FOR SUSPENSION | 200 mg | ORAL | NDA | 17 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-3150 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | NDA | 17 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-4061 | TABLET, FILM COATED | 250 mg | ORAL | NDA | 17 sections |
Zithromax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-9500 | TABLET, FILM COATED | 250 mg | ORAL | UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE | 19 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2026 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 17 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2027 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 17 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-0144 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 16 sections |
azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2370 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 17 sections |
azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2395 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 17 sections |
Azithromycin Dihydrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2750 | TABLET, COATED | 500 mg | ORAL | Unapproved drug for use in drug shortage | 2 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-1496 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 19 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-1497 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-1941 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 19 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5776 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 17 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5789 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 17 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5793 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-8089 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 17 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-8090 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 17 sections |
Azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-8091 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 17 sections |
Azithromycin Dihydrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6405 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 19 sections |
azithromycin monohydrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6708 | TABLET | 250 mg | ORAL | ANDA | 17 sections |
azithromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-648 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | NDA AUTHORIZED GENERIC | 18 sections |